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Background: Posterior reversible encephalopathy syndrome (PRES) has been increasingly identified in patients with
systemic lupus erythematosus (SLE) owing to the advance in neuroimaging techniques. Prompt diagnosis is pivotal
to improve its outcome. To analyze the clinical and radiographic profile of PRES in patients with SLE and search for
the appropriate treatment strategy PRES in SLE.
Methods: SLE patients who fulfilled the diagnostic criteria for PRES from August 2008 to January 2011 were
evaluated at baseline, and followed to determine clinical outcomes. Data were analysis on clinical characteristics,
laboratory abnormalities, treatment details, and outcomes.
Results: Ten episodes of PRES in patients with SLE were identified. All patients were female, mean age of onset
was 22.93 ± 2.48 years, and SLEDAI at the onset of PRES were 25.8 ± 5.7. All cases had acute onset of headache,
altered mental status, stupor, vomiting, cortical blindness and seizures. Neurological symptoms were the initial
manifestation of SLE in three cases. Head magnetic resonance imaging (MRI) demonstrated posterior white matter
edema involving the parietal, temporal and occipital lobes, which were more conspicuous on T2 weighted spin
echo and diffusion-weighted MR imaging (DWI) than on computed tomography (CT) scan. Complete clinical and
radiographic recovery was observed in 8 patients after prompt treatment with corticosteroids.
Conclusions: PRES might be due to lupus per se besides other traditional causative factors such as hypertension.
PRES might be an underestimated variant of “reversible neurological deficits” in SLE. Prompt recognition and timely
management is important to prevent permanent neurological deficits.
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Systemic lupus erythematosus (SLE) is an autoimmune
disease that can affect the central nervous system (CNS)
[1]. Neuropsychiatric manifestations vary from severe
neurological and psychiatric disorders to more subtle signs
such as headache, mood disorders and defects in cognitive
function [2-6]. The presentations as well as the underlying* Correspondence: zhangfccra@yahoo.com.cn
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reproduction in any medium, provided the orimmunopathogenic mechanisms can be heterogeneous and
therefore pose diagnostic and therapeutic dilemmas.
Posterior reversible encephalopathy syndrome (PRES)
was first reported by Aisen et al. in 1985 [7], which was
a clinical entity characterized by headache, nausea,
vomiting, seizures, conscious disturbance and visual dis-
order with predominantly white matter abnormalities of
the parieto-occipital lobes on neuroimaging [8,9]. PRES
could be associated with several conditions, including
hypertensive encephalopathy, eclampsia, immunosup-
pressive drugs and inflammatory disorders, and was re-
versible if treated promptly [8-12]. Literature review
showed that severe hypertension (> 170/110 mmHg) andThis is an Open Access article distributed under the terms of the Creative
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reported cases of SLE with PRES, whereas SLE patients
might also develop reversible focal deficits that respond to
steroid therapy [13]. The peculiar role of SLE itself in the
occurrence of PRES was not clear since PRES could be a
manifestation of lupus disease activity or a consequence of
immunomodulatory therapy, making the diagnosis and
treatment challenging. With the development of MRI
techniques, there was a high likelihood of presentation of
PRES to a rheumatologist. It was important to recognize
the condition early in order to minimize potential for irre-
versible central nervous system damage.
Here, we analyzed the clinical data of 10 cases of SLE
with PRES, systematically reviewed the pathogenesis and
treatment patients with SLE-associated PRES reported in
the literature. The aims of the present study were to reveal
the relationship between PRES and SLE, to search for the
appropriate treatment strategy PRES in SLE.
Methods
We studied the clinical data and neuroimaging of SLE
patients with CNS involvement followed in department of
Rheumatology of affiliated hospital Qingdao University
Medical College from August 2008 to January 2011. Only
SLE patients with PRES were selected, diagnosed accord-
ing to the clinical and neuroradiological criteria reported
in the literature. The abnormalities on imaging were
defined as multiple cortico-subcortical areas of low white-
matter attenuation on CT scans and as T1-weighted
hypointense and T2-weighted hyperintense areas on MRI
scans involving the occipital and parietal lobes bilaterally
that had partially or completely resolved on follow-up
scanning, when subsequent images were available. The
clinical symptoms also tended to almost complete reso-
lution after treatment [8,9]. MRI and/or CT of patients
showed normal despite pronounced neuropsychiatric
symptoms, and repeat MRI should be done within 2 weeks.
All patients fulfilled the American College of Rheumatology
(ACR) classification criteria for SLE [14], and disease activ-
ity at the time of the PRES episode was calculated using
SLE Disease Activity Index (SLEDAI) [15]. Non-SLE
patients, hypertensive encephalopathy, uremic encephalop-
athy, ischemic stroke and CNS infection were ruled out.
A brain MRI was performed with a 1.5 T GE Vectra
and a standard head coil. Fast-Spin-echo T2-weighted
(TR/TE/numbers of excitation = 2800/102/2), Spinecho
PD-weighted (3000/40/2), Fast-Spin-echo T1-FLAIR-
weighted (TR/TI/TE/numbers of excitation = 1750/
720/15/2), and T2-FLAIR-weighted (TR/TI/TE/num-
bers of excitation = 8400/2100/125/1) sequences were
performed in the axial and coronal planes, with 5 mm
slice thickness. The imaging sequence for DWI was
single-shot spinecho echo-planar imaging (4600/≥30
repetition time/echo time) with diffusion sensitivitiesb = 0 and b = 1,000 s/mm2. The diffusion gradients were
applied sequentially in three orthogonal directions to gener-
ate three sets of axial diffusion-weighted MR imaging
(DWI). Sections (5 mm thick) with 1.5 mm interslice gaps,
24 cm field of view, and 128 × 130 matrix were used for all
scans. The scan time was 40 s. A composite isotropic trace
image was made by multiplying the three DWI together
and taking the cubic root of the result to remove the effects
of diffusion anisotropy. Interpretations were made using
three sets of DWI and the composite isotropic trace image.
A non-contrast CT scan (Sensation 64, Siemens, Erlangen,
Germany) was also available in two cases. All studies were
evaluated by two expert neuroradiologists.
This study protocol was approved by the Research
Ethics Committee of The Affiliation Hospital of QingDao
University Medical College and followed the ethical guide-
lines of the 1975 Declaration of Helsinki and subsequent
ones [16]. All patients gave written informed consent to
participate in this study.
Results
Patient characteristics and clinical presentations
During the study period 732 consecutive patients were
previous or newly diagnosis cases of SLE. We identified 10
patients with SLE-PRES represented 1.4% of all SLE
consultations. All were female and mean age of onset was
22.93 ± 2.48 years. Three cases had PRES as a part of their
initial presentation of lupus. Among 10 patients, 8 had
seizures, 6 had coma, 3 had vomiting and headache, 2 had
bilateral cortical blindness, and 1 had stupor. The eight
patients in our series had hypertension. Before the onset
of PRES, 5 had hypertension and only one patient has
severe hypertension (> 170/110 mmHg). After the onset
of neurologic symptoms, two patients present severity
hypertension (Table 1).
Patients with positive serum anti-SSA, anti-SSB, anti-
dsDNA, antiphospholipid (aPL), anti-RNP/Sm, anti-Sm
and anti-Nucleosome antibodies were 7/10, 2/10, 6/10, 4/
10, 3/10, 2/10, 2/10, respectively. Eight patients (80%) had
a history of new or previously diagnosis lupus nephritis,
hypoproteinemia as well as hypocomplementemia, and 2
had renal incompetency. All patients had activated disease
at onset of PRES (SLEDAI range 13–38). Lumbar punc-
ture was carried on 8 patients, and two patients were
demonstrated opening pressure beyond 180mm H2O.
Cerebrospinal fluid examination revealed no abnormality
(normal protein and glucose concentration with negative
pathogenic finding).
Neuroimaging findings
All patients underwent cranial imaging studies; 1 under-
went only CT scanning, 8 only MRI scanning, and 1 both
CT and MRI scanning. Nine patients (9/10) had the initial
diagnosis of PRES based on MRI findings of T2-weighted
Table 1 Clinical and laboratory characteristics
10 episodes, no. (%)
Demographics
Age at onset (years) 22.93 ± 2.48 *
Female 10 (100)
SLE characteristics









Reynaud’s phenomena 4 (40)
SLEDAI 25.8 ± 5.7*
Associated risk factors
Acute hypertension 8 (80)
<160/100 mmHg 5 (50)
≥170/110 mmHg 3 (30)
























Methylprednisolone pulses 8 (80)
Table 1 Clinical and laboratory characteristics (Continued)
Cyclophosphamide 8 (80)
Outcome
Complete neurological recovery 8 (80)
Residual neurological deficit 1(10)
Death 1(10)
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index [23] aPL:
antiphospholipid antibodies. Mean and S.D.
b.At clinical onset.
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patient (1/10) had the diagnosis based only on CT find-
ings due to rapidly progressive disease. The occipital/
parietal and/or cerebellar involvements were found in
all 10 patients (100%), with 4 patients (40%) had abnor-
malities of anterior circulation. Six patients had diffused
bilateral gray- and white-matter changes that were more
prominent on T2-W imaging and high DWI signal in-
tensity (Table 2) (Figure 1). One patient had a right oc-
cipital hematoma on CT (Figure 2).
Interestingly, MRI of 2 patients showed normal
despite pronounced neuropsychiatric symptoms, and
a follow-up MRI suggested predominantly posterior
signal abnormalities after 2 weeks (Figure 3). Follow
up imaging studies were performed in 9 patientsTable 2 Imaging characteristics
10 episodes, no. (%)
Edema location
Occipital lobes 10 (100)
Unilateral 0
Bilateral 10
Parietal lobes 8 (80)
Unilateral 0
Bilateral 8












High signal DWI 4 (40)
Cortical involvement 6 (60)
Diffusion weighted image (DWI).
Figure 1 MRI of a 24 year-old SLE patient who presented with
seizure. T2-weighted image (A) shows high signal lesions in deep
and subcortical white matter bilaterally frontal and parietooccipital
but predominantly posteriorly. Diffusion-weighted image (B) shows
low-signal intensity area in corresponding lesion areas.
Corresponding apparent diffusion coefficient (ADC) map (C) reveals
high signal intensity area corresponding to low-signal area on
diffusion-weighted image. Follow-up T2-weighted image
(D) obtained 3 months after (A) shows complete resolution.
Figure 2 CT of a 19 year-old SLE patient who presented with
coma. CT image on brain show showing bilateral hypodensities
involving gray and white matter in posterior circulation territories as
well as a right occipital hematoma (arrow).
Figure 3 MRI of a 19 year-old SLE patient who presented with
stupor. T2-weighted image (A) and Diffusion-weighted image (B)
show normal. After 2 weeks repeat MRI, T2-weighted image
(C) shows high signal lesions in bilaterally temporooccipital white
matter. DWI (D) shows lesion isointensity. Follow-up T2-weighted
image (C) obtained 2 week after (E) reveals almost resolution of
high signal area in bilaterally lesion region. DWI (F) reveals lesion
isointensity.
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cantly reduction in vasogenic edema in all these
cases (Figure 1D).Treatment and outcome
Eight patients were treated with methylprednisolone
pulses (1 g/day for 3 days) as well as intravenous
gamma-globulin (400mg g/kg/day for 3 days) fol-
lowed by oral prednisone (0.5–1.0mg/kg/day). After
pulse treatment, eight patients were treated with
cyclophosphamide (400mg/m2/week). Two patients
were treated with methylprednisolone (1.0mg/kg/day)
during acute phase in the department of emergency.
For those patients with acute hypertension, potent
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eral supportive measures.
Complete clinic-neruroradiographic recovery occurred
in 8 patients after treatment. One patient resulted in
refractory vomiting due to delayed diagnosis and therapy,
notwithstanding neruroradiographic recovery at followup.
One patient died of the acute episode of SLE.
Discussion and conclusions
With advance in neuroimaging techniques, PRES has been
accumulating identified over the past decade [8,17]. The
similarities of the clinical manifestations between PRES,
neuropsychiatric SLE (NPSLE) and lupus-related compli-
cations CNS, such as CNS infection and psychiatric condi-
tions, often pose a diagnostic and therapeutic challenge
for rheumatologist. The differential diagnosis between
these entities is important, as the first requires immuno-
suppressive therapy, which should be avoided in the later
situation [18,19].
The exact pathophysiological mechanism of PRES
remains uncertain [20]. To date, three hypotheses have
been proposed, which include: (i) cerebral vasoconstriction
with subsequent infarcts of the brain, (ii) failure of cerebral
autoregulation with consequent vasogenic oedema, and (iii)
endothelial damage with disruption of the blood–brain
barrier causing fluid and protein transudation in the brain
[8,20-22]. The pathophysiology of PRES in SLE is also less
well understood. In most cases of SLE-related PRES, immu-
nosuppresants used to treat the SLE were suggested as
causative factors, though lupus itself or SLE-related hyper-
tension, antiphospholipid antibodies or renal failure might
also be contributive. Abnormal endothelial activation,
dysfunction and leukocyte tracking have recently been
documented to cause brain and systemic hypoperfusion,
which may be causative factors for PRES in SLE [21,23-30].
On the other hand, endothelial cell activation is one of
the pathogenic hallmarks of NPSLE. It usually occurs after
exposure to interleukin 1 (IL-1) and TNF-α, and may be
enhanced by local release of IL-1 and IL-6 [31]. SLE
patients with high SLEDAI have increased serum levels of
TNF-α and other pro-inflammatory cytokines that may
stimulate endothelial cells of intracranial vessels and
astrocytes to produce nitric oxide (NO), causing blood–
brain barrier (BBB) damage and plasma leakage [32]. In
some cases the endothelial dysfunction together with
hemodynamic factors may allow the escape of blood
plasma and large amounts of red blood cells resulting in
secondary parenchymal hematoma [27]. Histopathology
showed the PRES manifestation result from NPSLE were
due to focal cerebral edema associated with blood vessel
injury and ischemic changes, although in many cases histo-
pathology did not demonstrate specific lesions [28].
The occurrence of autoantibodies to SSA have been
linked with vasculitis, and aPL have been involved inabnormal endothelial activation [33-35]. Our study also
showed that the occurrence of anti-SSA antibodies, hypo-
proteinemia and hypocomplementemia might be associated
with PRES. Accordingly the cause of PRES in SLE was
probably due to multiple factors including lupus disease ac-
tivity, hypertension, nephritis, and/or medications. Most
reports had ascribed various immunosuppressive medica-
tions as causative factors. However SLE patients who were
in need of immunosuppressants treatment often had ac-
tive and severe disease [25,27,36], PRES could also occur
in new-onset, activity SLE as well as an absolute increase
in blood pressure [27]. Furthermore our series had one
main distinguishing feature compared with the available lit-
erature: only 3 patients presented with severe hypertension
(> 170/110 mmHg) including 2 patients had severity
hypertension after the onset of PRES, compared with 95%
in the reported literature. A cytotoxic effect of SLE could
explain why PRES might occur in the absence of severe
hypertension [11,37-39]. Consequently PRES might de-
velop as the initial manifestation of SLE per se instead of
complication of medications.
SLE patients might develop reversible focal neurological
deficits, which responded to steroid therapy (Figure 4)
[13,40-42]. On the other hand, though the subcortical and
deep white matter of the posterior circulation supplied
regions of the brain were usually affected in PRES, involve-
ment of the brainstem, cerebellum, basal ganglia, frontal
and temporal lobes and the cortex had also been reported
in up to 56% in patients with clinical features of PRES
[8,43-46]. Atypical lesion location with cortical and infra-
tentorial involvement or involvement of its anterior circu-
lation was not uncommon [47], which also were found in
our cohort. Interesting despite pronounced neuropsychi-
atric symptoms, some patients had unremarkable MRI
and CT scans, which were no correlate for the neuro-
logical symptoms. The possible caused for the clinico-
neuroradiological discrepancies [48]. If conventional MRI
findings were normal or did not provide an explanation
for neuropsychiatric sign and symptoms, repeated and
advanced neuroimaging might be considered. Hence, the
right scan should be performed at the right time for PRES
patients [49]. PRES in SLE might be an underestimated
varied of “reversible neurological deficits”, which predom-
inantly involved in posterior circulation.
The typical MRI features of PRES are diffuse hyperin-
tensities on T2-weighted and fluid attenuated inversion
recovery (FLAIR) images in the white matter in the
posterior areas of the cerebral hemispheres, which spare
the calcarine and paramedian occipital lobe structures and
are reversible [8]. In recent years, another MR technique,
echoplanar DWI findings are used in the diagnosis of
PRES [50]. Regions with vasogenic edema show marked
hyperintensity on apparent diffusion coefficient (ADC)
and mostly iso or hypointensity on DWI [27,51]. Lack of
Figure 4 Brain CT and MRI on admission and after treatment in a 26 year-old SLE patient who presented with seizure. CT (A) shows
normal but T2-weighted image (B) shows high signal lesions in subcortical left centroparietal white matter. On contrast-enhanced T1-weighted
sequence (C), there is minimal enhancement at the periphery. Diffusion-weighted image (D) shows high-signal intensity area in corresponding
lesion areas. Corresponding ADC map (E) reveals high signal intensity area. The abnormal lesion completely diminished in T2-weighted image
(F) after 8 months of steroid therapy. DWI (G) shows high signal lesions and ADC (H) reveals lesion low intensity.
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DWI suggested potential reversibility. DWI can further aid
in distinguishing vasogenic edema in PRES from the cyto-
toxic edema associated with early infracts. Cytotoxic edema
has high signal intensity on DWI, due to decreased ADC,
while vasogenic edema has low to intermediate signal
intensity [52]. Nevertheless the lesions of some patients
challenge with this knowledge, an increase in T2 signal
within regions of vasogenic edema could cause slight DW1
hyperintensity [52-54]. The extent of combined T2 and
DWI signal abnormalities associated with patient outcome
[55]. However, whether DWI was specific in the diagnosis
of patients with PRES remain to be determined [56]. Thus
the exact changes detected by use of DWI in patients with
PRES should be further investigation
The management of PRES in SLE is dependent on
etiology. In hypertension-related and drug-induced PRES,
the key to effective therapeutic includes prompt withdraw
of offending agent aggressive control of blood pressure,
timely anti-convulsive therapy of seizures and temporary
renal support. Whereas for SLE related PRES, vigorous
treatment with corticosteroids plus cyclophosphamide is
directed by lupus-related major organ manifestations.
Although PRES is reversible once treatment is instituted,
delayed diagnosis and therapy may lead to death orirreversible neurological deficit, as also shown in our series
[11,37,38]. Therefore prompt recognition and timely
rational management is important to prevent permanent
neurological deficits. Nevertheless controversy still exist
whether immunosuppression should be used in the
treatment of PRES in SLE, randomized controlled trials
should be performed for addressing the strategies of
therapy the situation.
In conclusion, PRES is not an exceptional condition and
might be an underestimated variant of “reversible neuro-
logical deficits” in SLE. With advances in radiologic im-
aging, there is a high likelihood of presentation of this
syndrome to a rheumatologist. Whether PRES is a present-
ing manifestation of SLE disease activity and of its treat-
ment or whether it represents a neurological symptoms of
SLE remain to be determined. It is important to recognize
the condition early in order to ensure a very high chance of
total neurological recovery in SLE patients with PRES.
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